Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma


Published: June 10, 2009
Abstract Views: 232
PDF: 219
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Lenalidomide 3-(4’aminoisoindo lin-1’-one)-1-piperidine-2, 6-dio ne (Revlimid®) is the lead compound in a new class of agents which are known as the immunomodulatory drugs.1 Lenalidomide has a similar chemical structure to thalidomide. Both drugs have a comparable in vitro profile; however, lenalidomide is more potent.

Supporting Agencies


Querfeld, C., Kuzel, T., Guitart, J., & Rosen, S. (2009). Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.485

Downloads

Citations